Reduced Stents and Stent-Grafts for the Management of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation

David C. Madoff; Michael J. Wallace

doi:10.1055/s-2005-925558

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2005; 22(4): 316-328
DOI: 10.1055/s-2005-925558

Reduced Stents and Stent-Grafts for the Management of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation

David C. Madoff¹ , Michael J. Wallace¹

¹Department of Diagnostic Radiology, Section of Interventional Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Abstract

ABSTRACT

Hepatic encephalopathy (HE) is a common complication encountered by patients after transjugular intrahepatic portosystemic shunt (TIPS) creation. Although most patients respond well to conservative medical therapy, up to 7% of patients do not and require more invasive therapeutic approaches. One option is emergent liver transplantation; however, most patients are not suitable candidates. During the past decade, various percutaneous techniques have been described that alter the hemodynamics through the TIPS by occluding it with coils or balloons or by reducing its diameter using constrained stents or stent-grafts. These endovascular techniques have produced symptomatic improvement in many patients with refractory HE, with either complete resolution or substantial reduction of HE symptoms that can be controlled with additional medical therapy. Unfortunately, despite all attempts, some patients remain incapacitated and ultimately die. Further research is necessary to improve our understanding of HE after TIPS creation so that less invasive and safer procedures can be developed to treat this difficult clinical problem.

KEYWORDS

Hepatic encephalopathy - hypertension-portal - liver-interventional procedure - shunts-portosystemic

Full Text

References

REFERENCES

1 Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis. 1996; 16 315-320
2 Zuckerman D A, Darcy M D, Bocchini T P, Hildebolt C F. Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. AJR Am J Roentgenol. 1997; 169 1727-1731
3 Forauer A R, McLean G K. Transjugular intrahepatic portosystemic shunt constraining stent for the treatment of refractory postprocedural encephalopathy: a simple design utilizing a Palmaz stent and Wallstent. J Vasc Interv Radiol. 1998; 9 443-446
4 Paz-Fumagalli R, Crain M R, Mewissen M W, Varma R R. Fatal hemodynamic consequences of therapeutic closure of a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol. 1994; 5 831-834
5 Haskal Z J, Cope C, Soulen M C, Shlansky-Goldberg R D, Baum R, Redd D CB. Intentional reversible thrombosis of transjugular intrahepatic portosystemic shunts. Radiology. 1995; 195 485-488
6 Kerlan Jr R K, LaBerge J M, Baker E L. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 1995; 6 917-921
7 Haskal Z J, Middlebrook M R. Creation of stenotic stent to reduce flow through a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol. 1994; 5 827-830
8 Hauenstein K H, Haag K, Ochs A, Langer M, Rossi M. The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology. 1995; 194 175-179
9 Gerbes A L, Waggershauser T, Holl J, Gulberg A, Fischer G, Reiser M. Experiences with novel techniques for reduction of stent flow in transjugular intrahepatic portosystemic shunts. Z Gastroenterol. 1998; 36 373-377
10 Madoff D C, Perez-Young I V, Wallace M J, Skolkin M D, Toombs B D. Management of TIPS-related refractory hepatic encephalopathy with reduced Wallgraft endoprostheses. J Vasc Interv Radiol. 2003; 14 369-374
11 Sanyal A J, Freedman A M, Shiffman M L, Purdum P P, Luketic V A, Cheatham A K. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology. 1994; 20 46-55
12 Garcia Jr N, Sanyal A J. Medical management of complications secondary to portal hypertension. In: Patel NH, Haskal ZJ, Kerlan RK Jr SCVIR Syllabus. Vol. XI: Portal Hypertension-Diagnosis and Interventions. 2nd ed. Fairfax, VA; The Society of Cardiovascular and Interventional Radiology 2001: 47-62
13 Ong J P, Mullen K D. Hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2001; 13 325-334
14 Blei A T, Cordoba J. The Practice Parameters Committee of the American College of Gastroenterology: hepatic encephalopathy. Am J Gastroenterol. 2001; 96 1968-1976
15 Rossle M, Piotraschke J. Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy. Dig Dis. 1996; 14(suppl 1) 12-19
16 Merli M, Riggio O, Dally L. PINC (Policentrica Italiana Nutrizione Cirrosi) . Does malnutrition affect survival in cirrhosis?. Hepatology. 1996; 23 1041-1046
17 Horst D, Grace N E, Conn H O et al.. Comparison of dietary protein with an oral, branched-chain enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology. 1984; 4 279-287
18 Van Thiel D H, Fagiuoli S, Wright H I et al.. Gastrointestinal transit in cirrhotic patients: effect of hepatic encephalopathy and its treatment. Hepatology. 1994; 19 67-71
19 Wolpert E, Phillips S F, Summerskill W H. Ammonia production in the human colon: effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med. 1970; 283 159-164
20 Rolachon A, Zarski J P, Lutz J M et al.. Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomized prospective study. Gastroenterol Clin Biol. 1994; 18 1057-1062
21 Clausen M R, Mortensen P B. Lactulose, disaccharides and colonic flora: clinical consequences. Drugs. 1997; 53 930-942
22 Uribe M, Campollo A, Vargas F et al.. Acidifying enemas (Lactitol and lactose) vs. non-acidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial. Hepatology. 1987; 7 639-643
23 Hawkins R A, Jessy J, Mans A M et al.. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol. 1994; 368 125-134
24 Gubbins G P, Moritz T E, Marsano L S et al.. Helicobacter pylori is a risk factor for hepatic encephalopathy in acute alcoholic hepatitis: the ammonia hypothesis revisited. The Veterans Administration Cooperative Study Group No. 275. Am J Gastroenterol. 1993; 88 1906-1910
25 Morgan M H, Read A E, Speller D C. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982; 23 1-7
26 Loft S, Sonne J, Dossing M, Andreasen P B. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol. 1987; 22 117-123
27 Schafer D F, Jones E A. Hepatic encephalopathy and the gamma-amino-butyric acid system. Lancet. 1982; 1 18-20
28 Basile A S, Hughes R D, Harrison P M et al.. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med. 1991; 325 473-478
29 Barbaro G, Di Lorenzo G, Soldini M et al.. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology. 1998; 28 374-378
30 Cordoba J, Blei A T. Treatment of hepatic encephalopathy. Am J Gastroenterol. 1997; 92 1429-1439
31 Potts III J R, Henderson J M, Millikan Jr W J, Sones P, Warren W D. Restoration of portal venous perfusion and reversal of encephalopathy by balloon occlusion of portal systemic shunt. Gastroenterology. 1984; 87 208-212
32 Jalan R, Hayes P C. Risk of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt. Radiology. 1995; 197 587
33 Brophy D, Haskal Z J. Simpler ways to deliver the stenotic stent for reducing TIPS flow. J Vasc Interv Radiol. 1998; 9 1032-1033
34 York J A. Re: Management of TIPS-related refractory hepatic encephalopathy with reduced Wallgraft endoprostheses. J Vasc Interv Radiol. 2003; 14 1469 , author reply 1469
35 Cejna M, Peck-Radosavljevic M, Thurnher S et al.. ePTFE-covered stent-grafts for revision of obstructed transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2002; 25 365-372
36 Haskal Z J, Brennecke L H. Transjugular intrahepatic portosystemic shunts formed with polyethylene terephthalate-covered stents: experimental evaluation in pigs. Radiology. 1999; 213 853-859
37 Otal P, Rousseau H, Vinel J-P, Ducoin H, Hassissene S, Joffre F. High occlusion rate in experimental transjugular intrahepatic portosystemic shunt created with a Dacron-covered nitinol stent. J Vasc Interv Radiol. 1999; 10 183-188
38 Haskal Z J, Weitraub J L, Susman J. Recurrent TIPS thrombosis after polyethylene stent-graft use and salvage with polytetraflouroethylene stent-grafts. J Vasc Interv Radiol. 2002; 13 1255-1259
39 Haskal Z J. Re: Management of TIPS-related refractory hepatic encephalopathy with reduced wallgraft endoprostheses. J Vasc Interv Radiol. 2004; 15 885 , author reply 885-886
40 Quaretti P, Michieletti E, Rossi S. Successful treatment of TIPS-induced hepatic failure with an hourglass stent-graft: a simple new technique for reducing shunt flow. J Vasc Interv Radiol. 2001; 12 887-890
41 Saket R R, Sze D Y, Razavi M K et al.. TIPS reduction with use of stents or stent-grafts. J Vasc Interv Radiol. 2004; 15 745-751

David C MadoffM.D.

Department of Diagnostic Imaging, Interventional Radiology Section

Unit 325, The University of Texas M.D. Anderson Cancer Center

1515 Holcombe Boulevard, Houston, TX 77030-4009